Summary of COVID-19 vaccine AEFI reports received in Saskatchewan

From December 2020 to November 30, 2024 1,407 reportable AEFI reports have been received following 3,264,551 doses of COVID-19 vaccines administered in SK with a reporting rate of 0.43 AEFIs per 1000 doses administered (0.043% of all doses administered). Refer to Tables 1 and 2 for more details.

AEFI Reports are updated every four weeks.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of November 2, 2024

Serious criteria include an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation.

Table 2: Cumulative Frequency of AEFIs Reported

Not inclusive of all AEFIs that can be reported

There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of November 30, 2024, 3 TTS, 36 myocarditis/pericarditis, 4 GBS and 0 CLS following COVID-19 immunizations have been reported in Saskatchewan.

Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca.